Caliper Life Sciences (NASDAQ:CALP) Will Struggle to Repeat 2010 Performance

Although they're coming off the top performance in their segment for 2010, the heightened expectations by investors for Caliper Life Sciences (NASDAQ:CALP) will probably be met with disappointment in 2011.

Leerink said, "The top performer in Life Science Tools & Diagnostics in 2010 (+150%), CALP has been appropriately credited for exceeding revenue expectations for several consecutive quarters, streamlining its product portfolio, and advancing key new product development programs (e.g., nextgen sequencing sample prep). We believe investor expectations for 2011 have heightened, and CALP's ability to similarly exceed those expectations during what we view as an integration and investment year will be more limited. Thus, we believe it appropriate to step to the sidelines on the stock."

Leerink Swann downgraded Caliper Life Sciences to "Market Perform." Caliper closed Friday at $5.64, down $0.34, or 5.69 percent. Leerink has a valuation range of $6.00-$6.25 on them.